On February 18, 2021 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that it will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 (Press release, Iovance Biotherapeutics, FEB 18, 2021, View Source [SID1234575285]). Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 9075827. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com.

On February 18, 2021 Pacira BioSciences, Inc. (NASDAQ:PCRX) reported that it will report its fourth quarter and year ended December 31, 2020 financial results before the open of the U.S. markets on Thursday, February 25, 2021 (Press release, Pacific Pharmaceuticals (Canada), FEB 18, 2021, View Source [SID1234575284]). Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, dial 1-877-845-0779 and provide the passcode 4864607. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com.

For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 4864607. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.

On February 18, 2021 FibroGen, Inc. (NASDAQ: FGEN) reported that it will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company’s corporate and financial performance (Press release, FibroGen, FEB 18, 2021, View Source [SID1234575283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the FibroGen website at View Source It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

A replay of the webcast and investor presentation will be available shortly after the call for a period of 30 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 3055327.

On February 18, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, reported that the company will participate in the upcoming Digital RAS-Targeted Drug Discovery Summit being held February 23-25, 2021 (Press release, Revolution Medicines, FEB 18, 2021, View Source [SID1234575280]). Steve Kelsey, M.D., president, research and development, will be a featured speaker during the virtual event and will provide a scientific update on the company’s first-in-class RAS(ON) Inhibitor programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Revolution Medicines recently announced the entry of two RAS(ON) Inhibitor programs into IND-enabling development: RMC-6291, a potent, oral and selective tri-complex inhibitor of KRASG12C(ON); and RMC-6236 a potent, oral and RAS-selective tri-complex KRASMULTI(ON) inhibitor.

Details of Revolution Medicines’ participation in the RAS-Targeted Drug Development Summit are as follows:

Presentation:

Title: Drugging the RAS(ON) Form of Diverse Oncogenic RAS Mutations
Presenter: Steve Kelsey, M.D., president, research and development
Date: Thursday, February 25, 2021
Time: 10:30 a.m. Eastern
Panel Discussion:

Title: Mechanisms of Resistance for Combination Therapies
Participant: Steve Kelsey, M.D., president, research and development
Date: Thursday, February 25, 2021
Time: 11:00 a.m. Eastern
Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at View Source

Revolution Medicines also reported that the company will participate in three upcoming investor conferences. Details of these events are as follows:

10th Annual SVB Leerink Global Healthcare Conference
Fireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairman
Conference date: February 22-26, 2021
Fireside chat time: 1:40 – 2:10 p.m. Eastern on February 25, 2021
Format: Virtual conference; webcast available
41st Annual Cowen Healthcare Conference
Fireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairman
Conference dates: March 1-4, 2021
Fireside chat time: 10:20 – 10:50 a.m. Eastern on March 3, 2021
Format: Virtual conference; webcast available
HC Wainwright Global Life Science Conference
Corporate presentation delivered by Mark A. Goldsmith, M.D., Ph.D., CEO and chairman
Conference dates: March 9-10, 2021
Presentation time: 7:00 a.m. Eastern on March 9, 2021
Format: Virtual conference; webcast available
To access the live webcasts of the fireside chats and corporate presentation at these investor conferences, please visit the "Events & Presentations" page within the Investors section of Revolution Medicines’ website at View Source Additionally, replays of the webcasts will be available on the "Events & Presentations" page of the Revolution Medicines’ website for at least 14 days following the conference.

On February 18, 2021 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported that it will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET (Press release, Intellia Therapeutics, FEB 18, 2021, View Source [SID1234575279]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To join the call:

U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call.
All participants should ask to be connected to the Intellia Therapeutics conference call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on February 25, 2021 at 12 p.m. ET.